{
    "clinical_study": {
        "@rank": "95890", 
        "acronym": "CKD-330(A)", 
        "arm_group": [
            {
                "arm_group_label": "A(Amlodipine 10mg)", 
                "arm_group_type": "Experimental", 
                "description": "Amlodipine 10mg 1T, PO, QD for 9days"
            }, 
            {
                "arm_group_label": "B(Amlodipine 10mg/Candesartan 32mg)", 
                "arm_group_type": "Experimental", 
                "description": "Amlodipine 10mg 1T, PO, QD for 9days/Candesartan 32mg 1T, PO, QD for 9days"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate a pharmacokinetic drug interaction and safety of\n      Amlodipine between free combination of Amlodipine and Candesartan and Amlodipine\n      monotherapy."
        }, 
        "brief_title": "CKD-330 Drug-Drug Interaction Study (Amlodipine)", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hypertension", 
        "condition_browse": {
            "mesh_term": "Hypertension"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Healthy male volunteer is between 20 and 45 years of age(inclusive) at the\n             pre-study(screening).\n\n          2. Volunteer who has 19kg/m\u00b2 \u2264 BMI(Body Mass Index) \u2264 26kg/m\u00b2\n\n          3. When volunteer in screening, Must include under the items.\n\n               1. 100 mmHg \u2264 sitting SBP <140 mmHg\n\n               2. 60 mmHg \u2264 sitting DBP < 90 mmHg\n\n               3. 45 bpm \u2264 Pulse < 95 bpm\n\n          4. Those who decided to join the clinical trials by themselves and to comply with the\n             precautions written consent.\n\n        Exclusion Criteria:\n\n          1. A previous history or present of clinically significant liver, renal,\n             gastro-intestinal, pulmonary, musculoskeletal, endocrine, neuropsychiatric,\n             hemato-oncological, cardiovascular disease.\n\n          2. Have a gastrointestinal disease history that can affect drug absorption(Crohn's\n             disease, Ulcers, GERD, Gastritis, etc.) or surgery (except simple appendectomy or\n             hernia surgery).\n\n          3. The history of clinically significant hypersensitivity reaction about Investigational\n             drugs and foods.\n\n          4. The history of drug abuse or drug abuse showed a positive for urine drug test.\n\n          5. Taking drugs have received any other investigational drug within 90 days prior to the\n             first dosing and metabolizing enzyme inducers or inhibitors such as barbitals within\n             30 days prior to the first dosing.\n\n          6. Whole blood donation within 60 days prior to the first dosing or plasma donation\n             within 30 days prior to the first dosing.\n\n          7. Taking drugs that clinical trials expected to affect within 14days or taking food\n             containing caffeine, grapefruit within 7days before the first dosing.\n\n          8. A heavy alcohol consumer(alcohol>3cup/day or 3times/week within last 1month)\n\n          9. A heavy smoker(cigarette>10cigarettes/day)\n\n         10. The subject has positive results of serum tests(Hepatitis B, C, HIV Test, Syphilis).\n\n         11. Have the Liver enzyme levels(AST, ALT) or Bilirubin, total results greater than 1.5\n             times the UNL.\n\n         12. Have the result of Creatinine clearance is less than 80mL/min(Cockcroft-Gault\n             equation applicable).\n\n         13. The result of 12-lead ECG in screening test is QTc>450msec.\n\n         14. An impossible one who participants in clinical trial by investigator's decision\n             including laboratory test result or another reason."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02064556", 
            "org_study_id": "144HPS13012"
        }, 
        "intervention": [
            {
                "arm_group_label": "B(Amlodipine 10mg/Candesartan 32mg)", 
                "description": "Amlodipine 10mg 1T, PO, QD for 9days", 
                "intervention_name": "Amlodipine 10mg", 
                "intervention_type": "Drug", 
                "other_name": "Norvasc Tab. 10mg"
            }, 
            {
                "arm_group_label": "A(Amlodipine 10mg)", 
                "description": "Amlodipine 10mg 1T, PO, QD for 9days/Candesartan 32mg 1T, PO, QD for 9days", 
                "intervention_name": "Amlodipine 10mg/Candesartan 32mg", 
                "intervention_type": "Drug", 
                "other_name": "Norvasc Tab. 10mg/Atacand Tab. 32mg"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Amlodipine", 
                "Candesartan", 
                "Candesartan cilexetil"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 14, 2014", 
        "location": {
            "contact": {
                "email": "ksbae@amc.seoul.kr", 
                "last_name": "Kyun-Seop Bae, Professor", 
                "phone": "82-2-3010-4611"
            }, 
            "contact_backup": {
                "email": "bestdoctor@amc.seoul.kr", 
                "last_name": "Yo-Han Kim, M.D.", 
                "phone": "82-2-3010-4615"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "state": "Songpa-gu"
                }, 
                "name": "Asan Medical Center"
            }, 
            "investigator": {
                "last_name": "Kyun-Seop Bae, Professor", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Open-label, Multiple Doses, Crossover Study to Evaluate a Pharmacokinetic Drug Interaction and Safety of Amlodipine Between Free Combination of Amlodipine and Candesartan and Amlodipine Monotherapy in Healthy Male Volunteers", 
        "overall_contact": {
            "email": "ksbae@amc.seoul.kr", 
            "last_name": "Kyun-Seop Bae, Professor", 
            "phone": "82-2-3010-4611"
        }, 
        "overall_contact_backup": {
            "email": "bestdoctor@amc.seoul.kr", 
            "last_name": "Yo-Han Kim, M.D.", 
            "phone": "82-2-3010-4615"
        }, 
        "overall_official": {
            "affiliation": "Asan Medical Center", 
            "last_name": "Kyun-Seop Bae, Professor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "AUC\u03c4,ss  of Amlodipine", 
                "safety_issue": "No", 
                "time_frame": "1D 0h, 8D 0h, 9D 0h, 1h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 10D 0h, 11D 0h"
            }, 
            {
                "measure": "Cmax,ss of  Amlodipine", 
                "safety_issue": "No", 
                "time_frame": "1D 0h, 8D 0h, 9D 0h, 1h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 10D 0h, 11D 0h"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02064556"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Tmax,ss of Amlodipine", 
            "safety_issue": "No", 
            "time_frame": "1D 0h, 8D 0h, 9D 0h, 1h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, 10h, 12h, 14h, 10D 0h, 11D 0h"
        }, 
        "source": "Chong Kun Dang Pharmaceutical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chong Kun Dang Pharmaceutical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}